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Abstract
Background: One strategy to help identify susceptibility genes for complex, multifactorial
diseases is to map disease loci in a representative animal model of the disorder. The nonobese
diabetic (NOD) mouse is a model for human type 1 diabetes. Linkage and congenic strain analyses
have identified several NOD mouse Idd (insulin dependent diabetes) loci, which have been mapped
to small chromosome intervals, for which the orthologous regions in the human genome can be
identified. Here, we have conducted re-sequencing and association analysis of six orthologous
genes identified in NOD Idd loci: NRAMP1/SLC11A1 (orthologous to Nramp1/Slc11a1 in Idd5.2),
FRAP1 (orthologous to Frap1 in Idd9.2), 4-1BB/CD137/TNFRSF9 (orthologous to 4-1bb/Cd137/
Tnrfrsf9 in Idd9.3), CD101/IGSF2 (orthologous to Cd101/Igsf2 in Idd10), B2M (orthologous to B2m
in Idd13) and VAV3 (orthologous to Vav3 in Idd18).
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BMC Genetics 2005, 6:9 http://www.biomedcentral.com/1471-2156/6/9Results: Re-sequencing of a total of 110 kb of DNA from 32 or 96 type 1 diabetes cases yielded
220 single nucleotide polymorphisms (SNPs). Sixty-five SNPs, including 54 informative tag SNPs,
and a microsatellite were selected and genotyped in up to 1,632 type 1 diabetes families and 1,709
cases and 1,829 controls.
Conclusion: None of the candidate regions showed evidence of association with type 1 diabetes
(P values > 0.2), indicating that common variation in these key candidate genes does not play a
major role in type 1 diabetes susceptibility in the European ancestry populations studied.
Background
Type 1 diabetes is a common, multifactorial disease
believed to be caused in a proportion of cases by an
autoimmune destruction of pancreatic β-cells by an
inflammatory infiltrate comprising T lymphocytes, den-
dritic cells and macrophages. This process results from a
complex interaction between genetic and environmental
risk factors. Genetically, it is under the control of the
major histocompatibility complex (MHC) [1] and many
other genes of smaller effect and mostly unknown
identity.
A murine model of type 1 diabetes, the NOD mouse,
spontaneously develops an autoimmune-mediated diabe-
tes that has many similarities to the human disease. It is
likely that components of the pathophysiology and
genetic predisposition are conserved across species, and
indeed two loci have already been shown to affect type 1
diabetes susceptibility in both species, namely the immu-
noregulatory MHC HLA class II and CTLA-4 genes. The
other causative gene(s) in the known Idd regions control-
ling type 1 diabetes susceptibility in the NOD mouse
could also determine susceptibility in humans, even
though this depends on the frequency of susceptibility
alleles in human populations, which affects statistical
power, and that the correct candidate gene has been cho-
sen from the Idd interval. These Idd intervals might con-
tain many genes, including several involved in the
immune response [2]. Nevertheless, in contrast to studies
in humans based on linkage, the localisation of a type 1
diabetes locus to a specific chromosome region in the
mouse genome using congenic strain breeding defines
with certainty a set of genes, one or more of which is def-
initely a susceptibility gene [3,4].
The central importance of T cell development and func-
tion in type 1 diabetes is evident from the susceptibility
genes identified so far. The MHC class II genes are impor-
tant etiologically in two rat models of type 1 diabetes, the
Biobreeding (BB) and KDP strains [5,6], the NOD mouse
strain [3] and in humans [1], with their essential function
not only in T cell activation and expansion but also in T
cell repertoire formation in the thymus and clonal dele-
tion of autoreactive cells. The BB rat type 1 diabetes sus-
ceptibility locus Ian4/Iddm1 [7] affects T lymphocyte
development whereas the Cblb (KDP rat) [8] and CTLA4
[9] (in humans and NOD mice) susceptibility genes high-
light the importance of the regulation of T cell activation,
expansion and homeostasis in the periphery, and perhaps
in the thymus as well.
In our selection of candidate genes within NOD congenic
intervals, we have, therefore, biased our choice towards
immune-related genes such as Il2 [2], Cd101 [10] and
Nramp1/Slc11a1 [11]. From each of Idd5.2 [11], Idd9.2
[12], Idd9.3 [12], Idd10 [10], Idd13 [13] and Idd18 [14] we
chose immune-associated functional candidate genes to
study in human type 1 diabetes: Nramp1/Slc11a1 from
Idd5.2 [11]; Frap1 from Idd9.2 (unpublished); 4-1bb/
Cd137/Tnfrsf9 from Idd9.3 [12] (unpublished); Cd101/
Igsf2 from Idd10 [10]; B2m from Idd13 [15] and Vav3 from
Idd18 (note that very recent congenic strain mapping
results indicate that the Idd18 interval contains only one
gene with known immunological function, namely the
VAV3 gene, and this will be published elsewhere). Table 1
summarises the main features of the six human candidate
genes.
Results and discussion
A tag SNP approach to test for association was adopted for
all genes, except for 4-1BB [16], in order to achieve cost-
savings in genotyping. A multi-locus test was used to eval-
uate the association between type 1 diabetes and the tag
SNPs due to linkage disequilibrium (LD) with one or
more causal variants [17]. Coding and untranslated
regions of NRAMP1 (MIM 600266), FRAP1 (MIM
601231), 4-1BB (MIM 602250), CD101 (MIM 604516),
B2M (MIM 109700) and VAV3 (MIM 605541) were re-
sequenced in 32 or 96 randomly chosen UK white
patients with type 1 diabetes to identify SNPs and for the
selection of tag SNPs. As LD between 4-1BB SNPs was
weak, eight out of nine common SNPs were genotyped
(minor allele frequency, MAF ≥ 0.03; one SNP could not
be genotyped due to assay technical difficulties) and ana-
lysed using single-locus tests.
A total of 110 kb of re-sequenced regions yielded 220
SNPs, including six deletion/insertion polymorphisms
(DIPs) (see Table 2 and Additional files 2, 3,4,5,6 and7).
No coding changes or obvious candidates for variants thatPage 2 of 8
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or B2M were observed. A synonymous change was
detected in exon 3 of NRAMP1 (MAF = 0.32) and a non-
synonymous SNP (nsSNP) in exon 15 (MAF = 0.02), caus-
ing a conservative amino acid change: Asp543Asn
(DIL5202/ss23142243). Interestingly, as in the case of its
mouse orthologue [10], several nsSNPs were discovered
in exons 3, 4, 5, and 8 of CD101 (see Additional file 5).
Re-sequencing of the three alternative transcripts of VAV3,
called VAV3 (27 exons), VAV3β (unique exon 1 and exons
4 to 27) and VAV3.1 (unique exon 18 and exons 19 to 27)
yielded six exonic SNPs (see Additional file 7). Two SNPs,
Pro611Ser (MAF = 0.13) and Gln613His (MAF = 0.13) are
located in the SH3 domain of the VAV3 protein and,
therefore, could result in VAV3 having altered protein
interactions. In order to facilitate the computation of the
selection of tag SNPs, VAV3 was divided into three sec-
tions as suggested by the pattern of LD across the gene.
Two common nsSNPs (MAF ≥ 0.05; DIL1521/rs7528153
and DIL3809/ss23142432) from VAV3 and a microsatel-
lite from NRAMP1 were genotyped a priori in the whole
Table 1: NOD mouse Idd loci, location of their human orthologous regions, and selected functional candidate genes.
Idd Mouse 
chromosome
Interval 
size (Mb)
Number of 
genes
Functional 
candidate 
genes in 
mouse Idd 
intervals
Location of 
human 
orthologous 
region
Human 
orthologue 
genes
Known gene function and 
previously reported disease 
associations
Idd5.2 1 1.7 47 Idd5.2: Nramp1/
Slc11a1
2q35 NRAMP1/
SLC11A1
Endosomal/lysosomal 
acidification and associated with 
protection from infectious 
disease and susceptibility to 
autoimmune disease
Idd9.2 4 1.1 13 Idd9.2: Frap1 1p32 FRAP1 FKBP12-rapamycin associated 
protein of mTOR. Candidate 
tumour suppressor gene, whose 
function in apoptosis is influenced 
by allelic variation
Idd9.3 4 1.2 13 Idd9.3: 4-1bb 1p36 4-1BB Role in enhancing and regulating 
CD4+, CD8+ T cells and dendritic 
cells
Idd10 3 0.95 7 Idd10: Cd101 1p12 CD101 Co-stimulatory receptor of T 
cells
Idd13 2 6 cM > 50* Idd13: B2m 15q21 B2M Required for antigen 
presentation by MHC class I 
molecules and the development 
of diabetes in NOD mice
Idd18 3 0.7 2 Idd18: Vav3 1p13-p21 VAV3 Guanine nucleotide exchange 
factor involved in signalling of T 
and B cell receptors
*Estimated number of genes. A version of this table is provided in Additional file 1 with the supporting published references (see Additional file 1).
Table 2: Summary of the re-sequencing study. Gene size, number of exons, amount of re-sequenced DNA for each gene (including 5' 
and 3' regions of gene), sequencing panel, and number of SNPs identified.
Locus Genomic size (kb) n exons Re-sequenced 
region (kb)
n cases re-
sequenced
n SNPs
NRAMP1 13.58 15 (7,13)* 12.13 32 20
4-1BB 20.50 8 13.66 96 23
FRAP1 60.98 58 30.88 32 55
CD101 34.61 10 15.90 96 31
B2M 6.61 4 9.33 32 13
VAV3 393.70 27 (25,10)* 27.69 96 78
Total 529.98 122 109.59 - 220
* Number of exons in splice variants. n, number.Page 3 of 8
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CD101 in step 1 families only (DIL3794/rs3754112). The
nsSNP DIL3810/ss23142433 in VAV3 was not tested
because it was in quite strong LD with DIL3809/
ss23142432 (R2 = 0.64), so that only DIL3809/
ss23142432 was genotyped. Note that in our tag
approach, the two VAV3 nsSNPs (DIL1521/rs7528153
and DIL3809/ss23142432) were chosen deliberately as
tag SNPs.
In a pragmatic, phased genotyping strategy, in step 1, the
multi-locus test P values for association between type 1
diabetes and candidate gene tag SNPs all exceeded 0.2, as
did the single-locus test P values for 4-1BB SNPs. Conse-
quently, we did not proceed to genotype in step 2 samples
for any of the candidate genes (Table 3 and 4). Note that
none of the nsSNPs of VAV3 and CD101 or the microsat-
ellite of NRAMP1 showed evidence of association (Table
5). Allele A3 of the NRAMP1 microsatellite promoter
(GT)n has previously shown linkage and association with
Table 3: Study design. Lengths of re-sequenced genomic regions, and number of tag SNPs or single SNPs genotyped in a pragmatic 
two-step genotyping design for NRAMP1, 4-1BB, FRAP1, CD101, B2M, and VAV3.
Locus Re-sequenced region (kb) n common SNPs* n tag SNPs Genotyping strategy (step 1 → step 2)
NRAMP1 12.13 12 4 Case-control → Family set 1+2
4-1BB 13.66 8 DIL4279/ss23142250 Family set 1
DIL4277/rs226476
DIL4569/rs226478
DIL4274/ss23142263
DIL4570/ss23142264
DIL4571/rs679563
DIL4273/ss23142265
DIL4272/ss23142270
FRAP1 30.88 21 6 Family set 1
CD101 15.9 18 8 Family set 1
B2M 9.33 10 8 Case-control → Family set 1
VAV3 27.69 19 (block 1)
18 (block 2)
15 (block 3)
7 (block 1)
11 (block 2)
10 (block 3)
Family set 1
*For the selection of tag SNPs, minor allele frequencies of 0.03 were used for 4-1BB, CD101 and FRAP1, and 0.05 for NRAMP1, B2M and VAV3. Note 
that the numbers of attempted and actual genotypes are given in Additional file 8. n, number.
Table 4: Disease association results. Multi-locus test P values, lengths of re-sequenced genomic regions, and number of tag SNPs or 
single SNPs genotyped in a two-step genotyping design for NRAMP1, 4-1BB, FRAP1, CD101, B2M, and VAV3.
Locus Multilocus test P value/ Single-locus TDT P value Case-control Combined test P value
Family set 1 Family set 1 + 2
NRAMP1 - 0.56 0.20 0.68
4-1BB 0.71 - - -
0.88 - - -
0.52 - - -
0.35 - - -
0.53 - - -
0.29 - - -
0.95 - - -
0.24 - - -
FRAP1 0.44 - - -
CD101 0.68 - - -
B2M 0.90 - 0.11 0.75
VAV3 0.26 (block 1) - - -
0.80 (block 2) - - -
0.86 (block 3) - - -Page 4 of 8
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susceptibility [18-20]. The relative risks of allele A3 and
genotype A3/A3 in our type 1 diabetes samples was 0.96
(95% CI = 0.94 – 1.17) and 0.90 (95% CI = 0.70 – 1.16),
respectively.
With regards to our association study in humans, intronic
and potential regulatory regions were not sequenced in
the candidate genes since these cover large genomic
regions, which will have to wait for much more extensive
polymorphism maps [21]. For example, for VAV3, which
spans almost 400 kb, less than 10% of the genomic region
of VAV3 was re-sequenced to identify SNPs. The general
importance of intronic and intergenic regulatory
sequences as candidates for disease susceptibility is well
recognised. Hence, potential unidentified causal variants
in introns or flanking regions of the genes may have been
missed, and remain a target for future analyses. Despite
finding no evidence of association, it remains possible
that there exists a common disease variant in one or more
of the six candidate genes tested, which either has an effect
smaller than would be detected with this study or is in
much weaker LD with the tag SNPs than any other SNP
known to us [22].
Finally, the possibility of one or more rare disease variants
in a locus needs to be considered [23]. The best candidates
for rare disease variants in the six genes studied here were
thus genotyped in an expanded case-control collection of
up to 3,704 type 1 diabetes cases and 3,930 controls:
DIL5202/ss23142243 causes a non-conservative change
in NRAMP (Asp543Asn, MAF = 0.02) and DIL3799/
ss23142349 in CD101 (Val839Ile; MAF = 0.03). For both
SNPs, P values above 0.05 were obtained (P = 0.19 for
DIL5202/ss23142243 and P = 0.80 for DIL3799/
ss23142349), therefore, making it less likely that these
rare variants contribute to susceptibility to type 1 diabetes.
Nevertheless, causal variants with MAFs less than 0.01
[24] may well remain undetected in our re-sequencing
panels of 32 or 96 case DNAs. However, the re-sequencing
of several hundred cases and controls is beyond the scope
of the present study in which we have investigated vari-
ants with MAF ≥ 0.03.
Conclusion
Taken together, these data make an association between
type 1 diabetes and common variation in coding and
untranslated regions of the six functional candidate genes
in the investigated human-mouse orthologue regions less
likely. Several possibilities may account for this. A gene
(or several genes) in an Idd interval may account for dis-
ease susceptibility in the NOD mouse, but the human
orthologous region may lack this susceptibility variant.
The scenario, in which candidate genes in the NOD Idd
interval may not necessarily be harbouring a functional,
causal variant in their human orthologue genes, was dis-
cussed previously [25]. It is also possible that the selected
candidate gene in the Idd interval may not be the gene
causing susceptibility to disease.
The tag SNP maps described here will be useful for associ-
ation studies of other diseases. They will be integrated into
future SNP maps encompassing the entire orthologous
regions and all regulatory sequences and genes encoded
within them.
Methods
Subjects
All family members were white and of European ancestral
origin. The type 1 diabetes families comprised two parents
and a least one affected child. The 748 type 1 diabetes
families used in 'step 1' were as described previously [26]:
472 UK Warren 1 multiplex and 276 multiplex Human
Biological Data Interchange families ascertained in the
U.S.A. The case-control DNA set for the tag SNP approach
consisted of 1,709 Caucasian type 1 diabetes cases, which
were recruited from across Britain in the Juvenile Diabetes
Research Foundation/Wellcome Trust funded UK Genetic
Resource Investigating Diabetes (GRID) study [27], and
1,829 population-based controls from the 1958 British
Birth Cohort (BBC) [28]. The mean age-at-onset of the
cases, with almost all under 16 years of age at diagnosis, is
Table 5: Association analysis of non-synonymous SNPs. SNPs with allele frequencies above 0.05 and the NRAMP1 (GT)n microsatellite 
in up to 1,476 families with at least one affected offspring. N, number; T, number of transmissions; NT, number of untransmitted 
alleles; %T, percentage transmission of minor allele from heterozygous parents to type 1 diabetes offspring (obtained by transmission/
disequilibrium test (TDT)); GTRR, genotype relative risk; P, probability value (two-sided).
Locus Marker ID Amino acid 
change/ alleles
Minor allele 
frequency
N families T NT %T PTDT PGTRR
VAV3 DIL1521 Thr293Ser/T>A 0.27 1 476 834 840 49.64 0.77 0.90
DIL3809 Pro611Ser/G>A 0.13 1 476 417 429 49.29 0.68 0.84
CD101 DIL3794 Asn225Ser/A>G 0.32 652 517 515 49.9 0.95 0.96
NRAMP1 (GT)n - - 1 476 - - - - 0.36Page 5 of 8
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BBC controls are part of an ongoing longitudinal study
and the subjects are British citizens born in a particular
week in 1958. In order to test association for type 1 diabe-
tes susceptibility and the rare variants in CD101 and
NRAMP1, DIL3799/ss23142349 and DIL5202/
ss23142243, a total of 3,704 type 1 diabetes cases and
3,930 controls were used.
For 'step 2' genotyping of NRAMP1, the 748 type 1 diabe-
tes families described above were used in addition to 343
multiplex/simplex families from the UK, 159 Norwegian
simplex families, 322 Romanian simplex families, and 60
multiplex families from the USA totalling the combined
DNA sets to 1,632 type 1 diabetes families, as described
previously [26].
Sequencing
Nested PCR products from DNA from 96 or 32 type 1 dia-
betes patients were sequenced using an Applied Biosys-
tems (ABI) 3700 capillary sequencer (Foster City, CA),
and SNPs identified using the Staden Package [29].
Genotyping
SNPs were genotyped using the Invader® assay (Third
Wave Technologies, Inc. Madison WI) [30] and TaqMan
MGB chemistry (ABI) [31]. The NRAMP1 microsatellite
was genotyped on an ABI3700 sequencer using
fluorescent primers as previously described [32]. Full
details of primers and probes used for genotyping are
available upon request. All genotyping data was double-
scored independently.
Annotation
Annotation of NRAMP1 (European Molecular Biology
Laboratory [EMBL] accession numbers D50402, D50403,
BC041787, L32185, BC033754), FRAP1 (UO88966), 4-
1BB (UO3387), CD101 (Z33642), B2M (BC032589) and
VAV3 (AF118887, VAV3; AF118886, VAV3β; AF118887,
VAV3.1) was performed by importing Ensembl informa-
tion into a temporary ACeDB database as described in
Burren et al. [33]. After confirmation of gene structures by
BLAST analysis, these were re-extracted in GFF format and
submitted to a local Gbrowse database (National Center
for Biotechnology Information build 34) (DIL annota-
tions viewable at T1DBase [34].
Statistical analysis
The program for the selection of tag SNPs [17] and associ-
ation analysis used here are implemented in the Stata sta-
tistical system and may be downloaded from our website
[35]. All genotyping data were in Hardy-Weinberg equi-
librium (P > 0.05).
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Additional File 2
SNPs, including two deletion/insertion polymorphisms, identified in 
NRAMP1. Novel SNPs are denoted by "ss" numbers and previously pub-
lished SNPs are denoted by "rs" numbers. Minor allele frequencies are 
based on the sequencing panel of 32 type 1 diabetes subjects. R2 values for 
non-typed SNPs. UTR, untranslated region.
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Additional File 5
SNPs identified in CD101. Novel SNPs are denoted by "ss" numbers and 
previously published SNPs are denoted by "rs" numbers. Minor allele fre-
quencies are based on the sequencing panel of 96 type 1 diabetes subjects. 
R2 values for non-typed SNPs. Note that DIL3969 has an allelic R2 < 0.80 
due to technical difficulties with the assay. UTR, untranslated region.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2156-6-9-S5.doc]
Additional File 7
SNPs, including four in/dels identified in VAV3. Novel SNPs are denoted 
by "ss" numbers and previously published SNPs are denoted by "rs" num-
bers. Minor allele frequencies are based on the sequencing panel of 96 type 
1 diabetes subjects. R2 values for non-typed SNPs. Note that DIL6496 and 
DIL6488 in block 1, and DIL1526 have allelic R2 values < 0.80, which 
was due to technical difficulties with those assays. UTR, untranslated 
region.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2156-6-9-S7.doc]
Additional File 1
Supporting published references for Table 1. NOD mouse Idd loci, the 
location of their human orthologous regions, and selected functional can-
didate gene within the Idd interval. *Estimated number of genes.
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